● neutral
Impact
PhaseApproved (Accelerated Approval)
Time to marketAlready approved and commercially available in the U.S. since October 2026.
TUDRIQEV vusolimogene oderparepvec Updated Nov 10
What to watch
TUDRIQEV is now a commercial-stage asset, so the focus shifts from regulatory binary to revenue execution. Watch the next quarterly earnings (likely late January 2027) for early sales figures, formulary adoption metrics, and the permanent J-code expected by April 2027. The confirmatory Phase 3 trial data timeline is the next major binary but has no announced readout date yet.
Bull case
- TUDRIQEV is only the second oncolytic virus therapy ever approved in the U.S. (after Amgen's Imlygic), giving Replimune a first-mover advantage in a novel modality for a large melanoma market.
- Early launch metrics are strong: more than 15 institutions prescribed TUDRIQEV in the first three weeks, and the stock jumped 17% on that news on October 29, 2026.
- Analyst consensus is bullish: 13 of 15 analysts rate it Buy/Strong Buy, with a mean price target of $23.33 (roughly in line with the current ~$23.28 price) and a high target of $31.
Bear case
- The drug was rejected twice by the FDA before finally securing accelerated approval, highlighting significant regulatory skepticism about the clinical data from the single-arm IGNYTE trial.
- Accelerated approval requires a confirmatory Phase 3 trial; if that trial fails or shows underwhelming results, the FDA could withdraw the indication.
- The company is still deeply unprofitable: a net loss of $57.1 million in Q2 FY2027 and $126.9 million in the first half of fiscal 2027, with no guarantee of when TUDRIQEV will reach profitability.